Tela Bio, Inc. Stock Price, News & Analysis

TELA Bio, Inc. announced positive findings from the BRAVO study presented at the Americas Hernia Society Annual Meeting. The data demonstrated a low incidence of surgical site infections and no hernia recurrences at 30 days post-operation using OviTex in ventral hernia repairs. The study involved 85 subjects, with 50% being obese and 16% having a history of surgical infections. Long-term results showed no hernia recurrences among the initial 20 subjects after two years. TELA's OviTex aims to address unmet needs in soft tissue reconstruction.

TELA Bio reported a revenue of $3.5 million for Q2 2020, marking a 6% increase from Q2 2019. Despite this growth, procedural volume declines due to the COVID-19 pandemic impacted results. Gross profit rose to $2.1 million, representing 59% of revenue, up from 58% in the previous year. Operating expenses increased to $7.3 million, leading to a loss from operations of $5.2 million. The company completed a public offering, raising approximately $45 million. Due to COVID-19 uncertainty, TELA will not provide 2020 financial guidance.

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in tissue reinforcement materials, will participate in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Management is set to present on August 13 at 1:30 p.m. ET. The conference will be held virtually, and interested parties can access the live webcast through the company's website. TELA Bio focuses on addressing unmet needs in soft tissue reconstruction with innovative products backed by extensive research.

TELA Bio, Inc. (NASDAQ: TELA) announced it will report its second quarter financial results for 2020 on August 12, 2020. A conference call and webcast led by management will follow at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in tissue reinforcement materials aimed at soft tissue reconstruction needs, emphasizing the advantages of its products over existing biologics and synthetic materials. The company’s offerings are backed by robust pre-clinical research.

Tela Bio, Inc. has successfully closed its public offering, issuing 3,000,000 shares at $16.00 each, translating to gross proceeds of $48 million before costs. The underwriters have a 30-day option to buy an additional 450,000 shares. Jefferies LLC and Piper Sandler & Co. led the offering management, with a registration statement filed with the SEC now effective. TELA specializes in innovative tissue reinforcement materials aimed at enhancing soft tissue reconstruction, with a focus on minimizing the limitations of existing products.

TELA Bio, Inc. announced the pricing of its underwritten public offering of 3,000,000 shares at $16.00 per share, aiming for gross proceeds of $48 million. The offering includes a 30-day option for underwriters to purchase an additional 450,000 shares. This offering is expected to close on June 30, 2020, pending customary conditions. Jefferies LLC and Piper Sandler & Co. are the book-running managers. TELA focuses on innovative tissue reinforcement materials for soft tissue reconstruction. The registration statement has been effective since June 25, 2020.

TELA Bio, Inc. (TELA) has announced a proposed underwritten public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares. The offering is subject to market conditions, and completion is uncertain. Jefferies LLC and Piper Sandler & Co. serve as joint book-running managers. A registration statement was filed with the SEC, but has not yet become effective, meaning sales cannot occur until it does. TELA aims to address unmet needs in soft tissue reconstruction with its innovative materials.

TELA Bio, Inc. (Nasdaq: TELA) announced its inclusion in the Russell 2000 Index, effective June 26, 2020. This milestone reflects TELA's growth trajectory in the medical technology sector, focusing on tissue reinforcement materials for soft tissue reconstruction. The company aims to enhance visibility among institutional investors, leveraging the approximately $9 trillion in assets that benchmark against the Russell U.S. Indices. CEO Tony Koblish emphasized this achievement as a sign of their operational and financial growth initiatives.

TELA Bio, Inc. (NASDAQ: TELA) announced two abstracts accepted for poster presentations at the virtual 20th Minimally Invasive Surgery Symposium (MISS) from June 9 to June 24, 2020. The presentations focus on the efficacy of OviTex® products in ventral hernia repair. One study reported low surgical site occurrence (SSO) and recurrence rates among patients, while another documented successful outcomes in a challenging patient population. TELA emphasizes OviTex's advantages over permanent synthetic materials, enhancing its value in soft tissue reconstruction.